Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Completed · Phase 1

Conditions studied: Hepatitis, Chronic, Hepatitis C Virus

In brief

Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.

Key facts

Study ID

NCT00671671

Run by

Pfizer

People needed

20

Starts

2008-04-01

Expected to finish

2008-12-01

Last updated by the study team

2014-01-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HCV Positive With HCV RNA>100,000 iu/ml Genotype 1; COHORT A- non responders or partial

You may not qualify if…

• HIV HBV co-infection Decompensated liver disease Liver disease due to causes other than HCV, AFP>200ng/ml

Where it is running

• Pfizer Investigational Site — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.